Access peer-reviewed publications, clinical validation studies, regulatory documents, and technical specifications
Spreadsheet showing market analysis and detailed calculations for Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM). Includes financial logic and assumptions for the business case.
View Financial Calculation SheetSummary of clinical survey conducted with 10 prestigious doctors in Jaipur, Rajasthan, on traumatic brain injury (TBI). This report captures their insights on diagnostic needs and device feature requirements, which directly influenced product design.
View Clinical Survey DocumentGoogle Slides presentation detailing the Bio-Stride biosensing platform, technical aspects of the microfluidic cartridge design, working methodology, and the full device testing flow.
View Technical PresentationComprehensive study on the temporal profiles of GFAP and UCH-L1 in patients with traumatic brain injury, published in JAMA Neurology.
View on JAMA NetworkMulticenter validation study demonstrating the clinical utility of GFAP and UCH-L1 for detecting traumatic brain injuries.
View in The Lancet NeurologyClinical validation of the Banyan Brain Trauma Indicator, the first FDA-cleared blood test for evaluating mild traumatic brain injury.
View Full StudyProspective study comparing the diagnostic accuracy of GFAP and S100β in detecting traumatic intracranial lesions on CT scans.
View in Clinical ChemistryUpdated white paper on electrochemical biosensor technology, with a special focus on AI-driven advances, sensor design, and biomarker detection in emergency diagnostics.
View Published Paper